Recruiting PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT05652686

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)

Sponsor: Hoffmann-La Roche

Conditions Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) Large Cell Neuroendocrine Cancer (LCNEC) Neuroendocrine Carcinomas (NEC) Neuroendocrine Prostate Cancer (NEPC) Small Cell Lung Cancer (SCLC)

Interventions Atezolizumab Carboplatin + Etoposide Paclitaxel. Peluntamig (PT217)

Updated 11 times since 2023 Last updated: Sep 18, 2025 Started: Sep 5, 2023 Primary completion: Dec 31, 2027 Completion: Aug 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05652686, this PHASE1/PHASE2 trial focuses on Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) and Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) and remains actively recruiting participants. Sponsored by Hoffmann-La Roche, it has been updated 11 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

11 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE1/PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
Feb 2025 — Jul 2025 [monthly]

Recruiting PHASE1/PHASE2
Dec 2024 — Feb 2025 [monthly]

Recruiting PHASE1/PHASE2

▶ Show 6 earlier versions

Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1 → PHASE1/PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Jun 2024 [monthly]

Recruiting PHASE1
Jul 2023 — Feb 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jan 2023 — Jul 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche
Phanes Therapeutics

Data source: Phanes Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Boston, United States , Chapel Hill, United States , Denver, United States , Duarte, United States , Fairfax, United States , Houston, United States , Oklahoma City, United States , Portland, United States , San Antonio, United States and 1 more location